1. Home
  2. SLXN vs IVDA Comparison

SLXN vs IVDA Comparison

Compare SLXN & IVDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • IVDA
  • Stock Information
  • Founded
  • SLXN 2008
  • IVDA 2003
  • Country
  • SLXN Israel
  • IVDA United States
  • Employees
  • SLXN N/A
  • IVDA N/A
  • Industry
  • SLXN
  • IVDA Computer Software: Prepackaged Software
  • Sector
  • SLXN
  • IVDA Technology
  • Exchange
  • SLXN NYSE
  • IVDA Nasdaq
  • Market Cap
  • SLXN 7.3M
  • IVDA 6.7M
  • IPO Year
  • SLXN N/A
  • IVDA N/A
  • Fundamental
  • Price
  • SLXN $11.30
  • IVDA $2.05
  • Analyst Decision
  • SLXN Strong Buy
  • IVDA
  • Analyst Count
  • SLXN 1
  • IVDA 0
  • Target Price
  • SLXN $5.00
  • IVDA N/A
  • AVG Volume (30 Days)
  • SLXN 821.0K
  • IVDA 77.2K
  • Earning Date
  • SLXN 08-21-2025
  • IVDA 08-13-2025
  • Dividend Yield
  • SLXN N/A
  • IVDA N/A
  • EPS Growth
  • SLXN N/A
  • IVDA N/A
  • EPS
  • SLXN N/A
  • IVDA N/A
  • Revenue
  • SLXN N/A
  • IVDA $7,148,449.00
  • Revenue This Year
  • SLXN N/A
  • IVDA $340.48
  • Revenue Next Year
  • SLXN N/A
  • IVDA N/A
  • P/E Ratio
  • SLXN N/A
  • IVDA N/A
  • Revenue Growth
  • SLXN N/A
  • IVDA 54.15
  • 52 Week Low
  • SLXN $0.58
  • IVDA $1.27
  • 52 Week High
  • SLXN $41.85
  • IVDA $8.05
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • IVDA 50.08
  • Support Level
  • SLXN N/A
  • IVDA $2.03
  • Resistance Level
  • SLXN N/A
  • IVDA $2.58
  • Average True Range (ATR)
  • SLXN 0.00
  • IVDA 0.20
  • MACD
  • SLXN 0.00
  • IVDA -0.02
  • Stochastic Oscillator
  • SLXN 0.00
  • IVDA 28.57

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

About IVDA Iveda Solutions Inc.

Iveda Solutions Inc offers smart city technologies globally, offering advanced AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients worldwide. The smart cities market, as well as the AI and IoT segments, are poised for significant growth in the coming years. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products).

Share on Social Networks: